CAN
AGRX

Claraphi Advisory Network’s Agile Therapeutics AGRX Stock Holding History

Claraphi Advisory Network’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7
Closed -$40K – 319
2020
Q2 		$40K Buy
+7
New +$36.4K 0.02% 277

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Claraphi Advisory Network's AGRX Position: Q3 2020 in Review

Claraphi Advisory Network sold out of Agile Therapeutics (AGRX) in Q3 2020, closing a stake of 7 shares — an estimated $40K sold.

Claraphi Advisory Network first reported a position in AGRX in Q2 2020 and held it in 1 quarter. The position peaked at $40K in Q2 2020. 75 funds tracked by Wall St. Rank hold AGRX as of Q3 2020.

  • Claraphi Advisory Network reported no remaining Agile Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Claraphi Advisory Network sold 7 Agile Therapeutics shares in Q3 2020, an estimated $40K.
  • Claraphi Advisory Network first reported a position in Agile Therapeutics in Q2 2020 and held it in 1 quarter.
  • Claraphi Advisory Network's Agile Therapeutics position peaked at $40K in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2020.

Based on Claraphi Advisory Network's 13F filing for Q3 2020, filed 13 Nov 2020.